AB SCIEX, a global leader in life science analytical technologies is collaborating with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, one of the world’s leading centers for biomedical research, to improve disease studies. The project is focused on better understanding cancer, diabetes and heart disease by advancing the study of proteins through the use of an emerging mass spectrometry platform currently under development by AB SCIEX.
Leading researcher Tony Pawson, a Kyoto Prize-winning scientist, and his team at the Lunenfeld are focusing their biomedical studies on analyzing complex protein interactions and modifications in the pathways and processes of communication between cells. The Lunenfeld is at the forefront of using mass spectrometrytechnology to apply protein research to enhance the field of cell biology and provide new insights into human diseases.
Through this collaboration, Lunenfeld researchers are using the life science industry’s first mass spectrometry system that combines qualitative and quantitative analysis at high resolution, high speed and high sensitivity with accurate mass. The result will be new workflows and applications that will be made available to the global life science community when AB SCIEX launches the new platform later this year. These workflows and applications will help expand the use of mass spectrometry across the life sciences.
Quotes Tony Pawson, distinguished investigator, Samuel Lunenfeld Research Institute “Mass spectrometry has incredible power to support human health by unraveling mysteries of the basic mechanisms of diseases. The new AB SCIEX accurate-mass technology is a significant leap forward in mass spectrometry tools for biomedical analysis, enabling us to better understand highly complex medical conditions and improve the quality of information emerging in the field of cell biology. This could lead to better ways to treat diseases in the future.”
Dave Hicks, vice president and general manager of Pharmaceuticals and Proteomics, AB SCIEX “Scientists around the world continue to adopt mass spectrometry to solve some of science’s biggest challenges. This collaboration between AB SCIEX and the Samuel Lunenfeld Research Institute is a great example of the power of this technology to understand more about the complexities of proteins and apply this knowledge to disease research. Through the development of workflows and applications, we will be able to deliver more effective ways of working that will be available on the industry’s most unique mass spectrometry platform.”
The Samuel Lunenfeld Research Institute of Mount Sinai Hospital, a University of Toronto affiliated research centre established in 1985, is one of the world's premier centres in biomedical research.
AB SCIEX is a global leader in the development of life science analytical technologies that help answer complex scientific challenges.